Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | enoyl-acyl carrier reductase ENR | 0.3284 | 0.5 | 0.5 |
Mycobacterium tuberculosis | NADH-dependent enoyl-[acyl-carrier-protein] reductase InhA (NADH-dependent enoyl-ACP reductase) | 0.3284 | 0.5 | 0.5 |
Plasmodium falciparum | enoyl-acyl carrier reductase | 0.3284 | 0.5 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | enoyl-ACP reductase | 0.3284 | 0.5 | 0.5 |
Mycobacterium leprae | NADH-DEPENDENT ENOYL-[ACYL-CARRIER-PROTEIN] REDUCTASE INHA (NADH-DEPENDENT ENOYL-ACP REDUCTASE) | 0.3284 | 0.5 | 0.5 |
Plasmodium vivax | enoyl-acyl carrier protein reductase | 0.3284 | 0.5 | 0.5 |
Trichomonas vaginalis | hypothetical protein | 0.3284 | 0.5 | 0.5 |
Mycobacterium ulcerans | enoyl-(acyl carrier protein) reductase | 0.3284 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | > 500 uM | Inhibitory concentration required to inhibit murine leukemia (L1210) cell line by 50% | ChEMBL. | 14667229 |
IC50 (functional) | > 500 uM | Inhibitory concentration required to inhibit mammary carcinoma (FM3A) cell line by 50% | ChEMBL. | 14667229 |
IC50 (functional) | > 500 uM | Inhibitory concentration required to inhibit human T-lymphocyte (Molt4/C8) cell line by 50% | ChEMBL. | 14667229 |
IC50 (functional) | > 500 uM | Inhibitory concentration required to inhibit human T-lymphocyte (CEM) cell line by 50% | ChEMBL. | 14667229 |
IC50 (functional) | > 500 uM | Inhibitory concentration required to inhibit human colon carcinoma (HT-29) cells by 50% | ChEMBL. | 14667229 |
IC50 (functional) | > 500 uM | Inhibitory concentration required to inhibit cervical carcinoma (HeLa) cells by 50% | ChEMBL. | 14667229 |
IC50 (functional) | > 500 uM | Inhibitory concentration required to inhibit melanoma (HBL) cells by 50% | ChEMBL. | 14667229 |
IC50 (functional) | > 500 uM | Inhibitory concentration required to inhibit laryngeal carcinoma (Hep2) cells by 50% | ChEMBL. | 14667229 |
IC50 (functional) | > 500 uM | Inhibitory concentration required to inhibit human colon carcinoma (SW620) cells by 50% | ChEMBL. | 14667229 |
IC50 (functional) | > 500 uM | Inhibitory concentration required to inhibit pancreatic carcinoma (MiaPaCa2) cells by 50% | ChEMBL. | 14667229 |
IC50 (functional) | > 500 uM | Inhibitory concentration required to inhibit diploid fibroblasts (WI38) by 50% | ChEMBL. | 14667229 |
IC50 (functional) | > 500 uM | Inhibitory concentration required to inhibit murine leukemia (L1210) cell line by 50% | ChEMBL. | 14667229 |
IC50 (functional) | > 500 uM | Inhibitory concentration required to inhibit mammary carcinoma (FM3A) cell line by 50% | ChEMBL. | 14667229 |
IC50 (functional) | > 500 uM | Inhibitory concentration required to inhibit human T-lymphocyte (Molt4/C8) cell line by 50% | ChEMBL. | 14667229 |
IC50 (functional) | > 500 uM | Inhibitory concentration required to inhibit human T-lymphocyte (CEM) cell line by 50% | ChEMBL. | 14667229 |
IC50 (functional) | > 500 uM | Inhibitory concentration required to inhibit human colon carcinoma (HT-29) cells by 50% | ChEMBL. | 14667229 |
IC50 (functional) | > 500 uM | Inhibitory concentration required to inhibit cervical carcinoma (HeLa) cells by 50% | ChEMBL. | 14667229 |
IC50 (functional) | > 500 uM | Inhibitory concentration required to inhibit melanoma (HBL) cells by 50% | ChEMBL. | 14667229 |
IC50 (functional) | > 500 uM | Inhibitory concentration required to inhibit laryngeal carcinoma (Hep2) cells by 50% | ChEMBL. | 14667229 |
IC50 (functional) | > 500 uM | Inhibitory concentration required to inhibit human colon carcinoma (SW620) cells by 50% | ChEMBL. | 14667229 |
IC50 (functional) | > 500 uM | Inhibitory concentration required to inhibit diploid fibroblasts (WI38) by 50% | ChEMBL. | 14667229 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.